Solanezumab May Cut Dementia’s Progression by 34%

The first details of how Eli Lilly’s solanezumab drug could slow the pace of brain decline for patients with early stage Alzheimer’s disease have emerged.

Data from pharmaceutical company Eli Lilly suggests its drug can cut the rate of the dementia’s progression by about a third.

The results, presented at the Alzheimer’s Association International Conference in the US, are being met with cautious optimism.

A new trial is due to report next year and should provide definitive evidence.

The death of brain cells in Alzheimer’s is currently unstoppable. Solanezumab may be able to keep them alive.

Current medication, such as Aricept (Donepezil), can manage only the symptoms of dementia by helping the dying brain cells function.

But solanezumab attacks the deformed proteins, called amyloid, that build up in the brain during Alzheimer’s.

It is thought the formation of sticky plaques of amyloid between nerve cells leads to damage and eventually brain cell death.

Solanezumab has long been the great hope of dementia research, yet an 18-month trial of the drug seemingly ended in failure in 2012.

However, when Eli Lilly looked more closely at the data, there were hints it could be working for patients in the earliest stages of the disease.

It appeared to slow progression by around 34% during the study.

So the company asked just over 1,000 of the patients in the original trial with mild Alzheimer’s to take the drug for another two years.

Positive results from this extension of the original trial have now been presented at the Alzheimer’s Association International Conference.

They show those taking the drugs the longest had the most benefit.

Eli Lilly also started a completely separate trial in mild patients in 2012, and these results could prove to be the definitive moment for the drug.

In the first stage of the original trial, which ended in failure, half of the patients with Alzheimer’s were given solanezumab and half were not.

A reanalysis of the cognition scores of the patients with mild Alzheimer’s suggested taking the drug had cut the rate of the disease’s progression by about 34%.

The implication is that the amount of cognitive decline normally seen in 18 months would take 24 months with the drug.

In the extension of the original trial, all of the 1,000-plus mild Alzheimer’s patients participating were given solanezumab.

At the end of the extension, half of them had been taking the drug for three and a half years while the other half had been taking it for two years.

The latest data shows those taking solanezumab for the longest time still had better scores of cognitive function.

This suggests the course of the disease was being slowed.

If the patients’ brains had continued to decline at the normal pace and the drug had been merely helping with symptoms, then all of the patients participating in the extension of the original trial – whether they had been taking solanezumab for three and a half or two years – would have had similar scores of cognitive function.